{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:07Z","timestamp":1793412007216,"version":"4.5.0"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,12,30]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real-world data on children with severe asthma is scarce. We report characteristics of children with severe asthma already on biologics, enrolled in the Severe Paediatric Asthma Collaborative in Europe, a clinical research collaboration of the European Respiratory Society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe patient's characteristics including asthma control assessed with Global Initiative for Asthma (GINA) criteria, composite asthma severity index (CASI), exacerbations, unscheduled medical attendances, lung function and quality of life in children on biologic treatment because of severe asthma. We also assessed previous biologics use. Forced expiratory volume in 1\u2005s, CASI, GINA, Paediatric Asthma Quality of Life Questionnaire score, exacerbations, unscheduled medical attendance and hospital admission comparisons in patients treated with different biologics were adjusted by age, sex and biologic therapy duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 250 children (median age 13.2\u2005years) recruited, 56.8% used omalizumab, 21.6% mepolizumab and 21.6% dupilumab. At enrolment, the dupilumab group was older (median 15.0\u2005years), while the omalizumab group had been on biologic treatment the longest (median 622\u2005days). Overall, 27% and 8% had partly controlled and uncontrolled asthma respectively, according to GINA. In the last 12\u2005months, 52% and 29% had at least one and two exacerbations, respectively; airflow obstruction was found in 33%. 10% were admitted to hospital due to exacerbation. A previous switch from another biologic was recorded in 16%, predominantly due to nonresponse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most children on biologics obtained good symptom control, but many still experienced asthma attacks. Switching between biologics was substantial. There is still an unmet need in severe paediatric asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00709-2024","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:10:06Z","timestamp":1741331406000},"page":"00709-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics"],"prefix":"10.1183","volume":"11","author":[{"given":"Norrice M.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle W.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Deschildre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"de Mir-Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigve","family":"Adalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Antonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscille","family":"Bierm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-542X","authenticated-orcid":false,"given":"Maynor","family":"Bravo-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin C.L.","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2284-1225","authenticated-orcid":false,"given":"Silvia","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Delestrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Diaz Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-1039","authenticated-orcid":false,"given":"Ralph","family":"Epaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Fenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-8519","authenticated-orcid":false,"given":"Valentina A.","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-7433","authenticated-orcid":false,"given":"Louise","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Labouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Chiara","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Licari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lopez Neyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Marguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mazenq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0341-5979","authenticated-orcid":false,"given":"Santiago","family":"P\u00e9rez Tarazona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Ramos","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-774X","authenticated-orcid":false,"given":"Cyril","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Valverde Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Verhulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Wanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-6472","authenticated-orcid":false,"given":"Franca","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2026012302550936000_11.3.00709-2024.1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00246"},{"key":"2026012302550936000_11.3.00709-2024.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01665-2018"},{"key":"2026012302550936000_11.3.00709-2024.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00008115"},{"key":"2026012302550936000_11.3.00709-2024.4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/pai.13484","article-title":"Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma","volume":"32","author":"Nieto Garcia","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"2026012302550936000_11.3.00709-2024.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002"},{"key":"2026012302550936000_11.3.00709-2024.6","doi-asserted-by":"crossref","first-page":"1033511","DOI":"10.3389\/fped.2022.1033511","article-title":"Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile","volume":"10","author":"Fenu","year":"2022","journal-title":"Front Pediatr"},{"key":"2026012302550936000_11.3.00709-2024.7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"2026012302550936000_11.3.00709-2024.8","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jaip.2023.12.006","article-title":"Dupilumab improves lung function parameters in pediatric type 2 asthma: Voyage study","volume":"12","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012302550936000_11.3.00709-2024.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"2026012302550936000_11.3.00709-2024.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"2026012302550936000_11.3.00709-2024.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA4720"},{"key":"2026012302550936000_11.3.00709-2024.12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma","volume":"10","author":"Porsbjerg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012302550936000_11.3.00709-2024.13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40272-023-00589-4","article-title":"Developments in the management of severe asthma in children and adolescents: focus on dupilumab and tezepelumab","volume":"25","author":"van Dijk","year":"2023","journal-title":"Paediatr Drugs"},{"key":"2026012302550936000_11.3.00709-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00143-2021"},{"key":"2026012302550936000_11.3.00709-2024.15","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.002018"},{"key":"2026012302550936000_11.3.00709-2024.16","unstructured":"GINA , Global Strategy for Asthma Management and Prevention 2022 Update. 2022. https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/07\/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf"},{"key":"2026012302550936000_11.3.00709-2024.17","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1212"},{"key":"2026012302550936000_11.3.00709-2024.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026012302550936000_11.3.00709-2024.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.962"},{"key":"2026012302550936000_11.3.00709-2024.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435967"},{"key":"2026012302550936000_11.3.00709-2024.21","doi-asserted-by":"crossref","first-page":"e2018172","DOI":"10.1590\/1984-0462\/2020\/38\/2018172","article-title":"Quality of life evaluation and associated factors in asthmatic children and adolescents attended in a specialized outpatient clinic","volume":"38","author":"Fontan","year":"2020","journal-title":"Rev Paul Pediatr"},{"key":"2026012302550936000_11.3.00709-2024.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-060ST"},{"key":"2026012302550936000_11.3.00709-2024.23","unstructured":"World Health Organization . BMI for age (5-19 years). Date last accessed: 4 September 2024. Date last updated: 2024. www.who.int\/tools\/growth-reference-data-for-5to19-years\/indicators\/bmi-for-age"},{"key":"2026012302550936000_11.3.00709-2024.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"2026012302550936000_11.3.00709-2024.25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaip.2022.02.002","article-title":"Personalized treatment of asthma: the importance of sex and gender differences","volume":"10","author":"Jenkins","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012302550936000_11.3.00709-2024.26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fped.2019.00301","article-title":"Transition for adolescents and young adults with asthma","volume":"7","author":"Withers","year":"2019","journal-title":"Front Pediatr"},{"key":"2026012302550936000_11.3.00709-2024.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149812"},{"key":"2026012302550936000_11.3.00709-2024.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"2026012302550936000_11.3.00709-2024.29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.alit.2021.01.001","article-title":"Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: a post-marketing surveillance","volume":"70","author":"Nakamura","year":"2021","journal-title":"Allergol Int"},{"key":"2026012302550936000_11.3.00709-2024.30","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026012302550936000_11.3.00709-2024.31","doi-asserted-by":"crossref","unstructured":"Khaleva E , Rattu A , Brightling C , et al. Development of core outcome measures sets for paediatric and adult severe asthma (COMSA). Eur Respir J 2023; 3; 61: 2200606. doi:10.1183\/13993003.00606-2022","DOI":"10.1183\/13993003.00606-2022"},{"key":"2026012302550936000_11.3.00709-2024.32","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00709-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:55:20Z","timestamp":1769165720000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00709-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1183\/23120541.00709-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00709-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}